Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to $1.6 million.

  • Lexaria Bioscience's Operating Expenses fell 4520.61% to $1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $11.3 million, marking a year-over-year increase of 4470.84%. This contributed to the annual value of $12.6 million for FY2025, which is 10255.56% up from last year.
  • Per Lexaria Bioscience's latest filing, its Operating Expenses stood at $1.6 million for Q4 2025, which was down 4520.61% from $2.9 million recorded in Q3 2025.
  • Lexaria Bioscience's Operating Expenses' 5-year high stood at $3.9 million during Q2 2025, with a 5-year trough of $813005.0 in Q1 2024.
  • In the last 5 years, Lexaria Bioscience's Operating Expenses had a median value of $1.8 million in 2024 and averaged $2.0 million.
  • Within the past 5 years, the most significant YoY rise in Lexaria Bioscience's Operating Expenses was 25977.79% (2025), while the steepest drop was 4520.61% (2025).
  • Quarter analysis of 5 years shows Lexaria Bioscience's Operating Expenses stood at $2.0 million in 2021, then fell by 11.65% to $1.8 million in 2022, then fell by 27.67% to $1.3 million in 2023, then soared by 123.39% to $2.9 million in 2024, then tumbled by 45.21% to $1.6 million in 2025.
  • Its Operating Expenses stands at $1.6 million for Q4 2025, versus $2.9 million for Q3 2025 and $3.9 million for Q2 2025.